- The shares of Biogen (NASDAQ: BIIB) have received a $238 price target from BMO Capital. These are the details.
The shares of Biogen (NASDAQ: BIIB) have received a $238 price target from BMO Capital. And BMO Capital analyst Evan David Seigerman reiterated a “Market Perform” rating on the shares following the company’s investor conference.
“Biogen investor conference takeaways: Biogen CEO Michel Vounatsos presented at a conference today and highlighted the potential scenarios ahead of the NCD final decision (April 12) and lecanemab readout in September,” wrote Seigerman in a research note. “Limited new information was shared, but we get the sense that the company is trying to draw attention to other parts of business (Immunology, Biosimilars, Digital Health) and away from AD/Neurology (elephant in the room), which does not invigorate confidence.”
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.